# US 10,478,108 B2 · Analyte monitoring device and methods of use > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,478,108 B2 - Document ID: US10478108B2 - Status: Granted - Kind: B2 - Application number: 15/017,565 - Filed: 2016-02-05 - Published: 2016-06-02 - Granted: 2019-11-19 - Earliest claimed: 2007-04-19 - Assignees: Abbott Diabetes Care Inc. - Applicants: Abbott Diabetes Care Inc. - Inventors: Howard Wolpert; Adam Heller - Web page: https://patentgrep.com/patent/US10478108B2 ## CPC - A61B 5/1486: using enzyme electrodes, e.g. with immobilised oxidase - A61B 5/1118: {Determining activity level} - A61B 5/14532: {for measuring glucose, e.g. by tissue impedance measurement} - A61B 5/14546: {for measuring analytes not otherwise provided for, e.g. ions, cytochromes} - A61B 5/14865: {invasive, e.g. introduced into the body by a catheter or needle or using implanted sensors} - A61B 5/4839: {combined with drug delivery} - A61B 5/7445: {Display arrangements, e.g. multiple display units} - A61M 5/1723: {using feedback of body parameters, e.g. blood sugar or pressure} - H10W 70/424: {Cross-sectional shapes (H10W70/481 takes precedence)} - H10W 74/111: {the semiconductor body being completely enclosed} - A61B 5/0002: {Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network (endoradiosondes A61B5/07)} - A61B 5/1473: invasive, e.g. introduced into the body by a catheter - A61B 5/7275: {Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor} - A61B 2560/0252: using ambient temperature - A61B 2560/063: Devices specially adapted for delivering implantable medical measuring apparatus - A61M 5/14244: {adapted to be carried by the patient, e.g. portable on the body} - A61M 2205/3569: sublocal, e.g. between console and disposable - A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D) - A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)} - H10W: GENERIC PACKAGES, INTERCONNECTIONS, CONNECTORS OR OTHER CONSTRUCTIONAL DETAILS OF DEVICES COVERED BY CLASS H10 ## Abstract An analyte monitor includes a sensor, a sensor control unit, and a display unit. The sensor has, for example, a substrate, a recessed channel formed in the substrate, and conductive material disposed in the recessed channel to form a working electrode. The sensor control unit typically has a housing adapted for placement on skin and is adapted to receive a portion of an electrochemical sensor. The sensor control unit also includes two or more conductive contacts disposed on the housing and configured for coupling to two or more contact pads on the sensor. A transmitter is disposed in the housing and coupled to the plurality of conductive contacts for transmitting data obtained using the sensor. The display unit has a receiver for receiving data transmitted by the transmitter of the sensor control unit and a display coupled to the receiver for displaying an indication of a level of an analyte. The analyte monitor may also be part of a drug delivery system to alter the level of the analyte based on the data obtained using the sensor. ## Claims ### Claim 1 A physiological monitoring system, comprising: an analyte sensor to generate signals corresponding to monitored analyte level in bodily fluid under a skin surface of a user; a motion detector to monitor an activity level of the user corresponding to a completed exercise activity by the user; a processor operatively coupled to the analyte sensor and the motion detector to determine a previously monitored variation in the analyte level monitored by the analyte sensor based on the monitored activity level of the user, to receive a user-determined bolus quantity, to enable a therapy device to deliver the user-determined bolus quantity, to determine that the determined previously monitored variation in the analyte level exceeds a predetermined threshold, and in response to the determined previously monitored variation in the analyte level exceeding the predetermined threshold, temporarily disable the therapy device from delivering the user-determined bolus quantity; and a user interface in signal communication with the processor to output a warning of an impending hypoglycemic condition based on the determined previously monitored variation in the analyte level based on the monitored activity level of the user, the user interface configured to output the warning by at least displaying a therapy information relating to the user-determined bolus quantity and a prompt to receive a user input to confirm that the user-determined bolus quantity should be delivered, the therapy information and the prompt to receive the user input being overlaid on a real-time depiction of the analyte level; wherein the processor is configured to, in response to the user input, re-enable the therapy device to deliver the user-determined bolus quantity. ### Claim 2 (depends on 1) The system of claim 1, wherein the activity level includes a level of exercise. ### Claim 3 (depends on 1) The system of claim 1, wherein when the processor determines an impending hypoglycemic condition, the processor is further configured to modify one or more medication administration related thresholds. ### Claim 4 (depends on 3) The system of claim 3, wherein the medication is insulin. ### Claim 5 (depends on 1) The system of claim 1, wherein the processor is configured to modify a medication administration related threshold based on a low blood glucose index. ### Claim 6 (depends on 1) The system of claim 1, wherein the processor is configured to determine an impending hypoglycemic condition when medication administration exceeding a predetermined threshold is detected. ### Claim 7 (depends on 1) The system of claim 1, wherein the processor is configured to determine the variation in the analyte level after exercise based on the activity level monitored with the motion detector. ### Claim 8 (depends on 1) The system of claim 1, wherein the analyte sensor comprises a plurality of electrodes including a working electrode comprising an analyte-responsive enzyme bonded to a polymer disposed on the working electrode. ### Claim 9 (depends on 8) The system of claim 8, wherein the analyte-responsive enzyme is chemically bonded to the polymer disposed on the working electrode. ### Claim 10 (depends on 8) The system of claim 8, wherein the working electrode comprises a mediator bonded to the polymer disposed on the working electrode. ### Claim 11 (depends on 10) The system of claim 10, wherein the mediator is crosslinked with the polymer disposed on the working electrode. ### Claim 12 (depends on 1) The system of claim 1, wherein the analyte sensor comprises a plurality of electrodes including a working electrode comprising a mediator bonded to a polymer disposed on the working electrode. ### Claim 13 A method, comprising: receiving analyte signals corresponding to monitored analyte level in bodily fluid under a skin surface of a user using an analyte sensor; receiving motion signals corresponding to an activity level of the user from a motion detector, the activity level corresponding to a completed exercise activity by the user; determining a previously monitored variation in the analyte level monitored by the analyte sensor based on the motion signals; receiving a user-determined bolus quantity; enabling a therapy device to deliver the user-determined bolus quantity; determining that the determined previously monitored variation in the analyte level exceeds a predetermined threshold; in response to the determined previously monitored variation in the analyte level exceeding the predetermined threshold, temporarily disabling the therapy device from delivering the user-determined bolus quantity; outputting information associated with an impending hypoglycemic condition based on the determined previously monitored variation in the analyte level, the information including a therapy information relating to the user-determined bolus quantity and a prompt to receive a user input to confirm that the user-determined bolus quantity should be delivered, the therapy information and the prompt to receive the user input being overlaid on a real-time depiction of the analyte level; and in response to the user input, re-enabling the therapy device to deliver the user-determined bolus quantity. ### Claim 14 (depends on 13) The method of claim 13, wherein the previously monitored variation in the analyte level monitored by the analyte sensor is determined in at least substantially real time. ### Claim 15 (depends on 13) The method of claim 13, further including modifying one or more medication administration related thresholds when an impending hypoglycemic condition is determined. ### Claim 16 (depends on 13) The method of claim 13, further including modifying a medication administration related threshold based on a low blood glucose index. ### Claim 17 (depends on 13) The method of claim 13, further including determining an impending hypoglycemic condition when medication administration exceeding a predetermined threshold is detected. ### Claim 18 (depends on 13) The method of claim 13, wherein the analyte sensor comprises a plurality of electrodes including a working electrode comprising an analyte-responsive enzyme bonded to a polymer disposed on the working electrode. ### Claim 19 (depends on 18) The method of claim 18, wherein the analyte-responsive enzyme is chemically bonded to the polymer disposed on the working electrode. ### Claim 20 (depends on 18) The method of claim 18, wherein the working electrode comprises a mediator bonded to the polymer disposed on the working electrode. ### Claim 21 (depends on 20) The method of claim 20, wherein the mediator is crosslinked with the polymer disposed on the working electrode. ### Claim 22 (depends on 1) The system of claim 1, wherein the processor is operatively coupled to the analyte sensor and the motion detector to determine the previously monitored variation in the analyte level monitored by the analyte sensor in at least substantially real time.